Upfront Payments in Biotech Deals
Executive Summary
How much are biotech companies receiving upfront on average from their collaborators, relative to the clinical phase of the product being licensed? To find out, we took 445 deals since 1989 in which an upfront payment was made and broke out the average upfront license fees and equity payments by clinical phase of the most advanced product licensed in the deal.